Success Metrics

Clinical Success Rate
50.0%

Based on 5 completed trials

Completion Rate
50%(5/10)
Active Trials
2(17%)
Results Posted
100%(5 trials)
Terminated
5(42%)

Phase Distribution

Ph phase_1
11
92%
Ph phase_2
1
8%

Phase Distribution

11

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
11(91.7%)
Phase 2Efficacy & side effects
1(8.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

5 of 10 finished

Non-Completion Rate

50.0%

5 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(5)
Terminated(5)

Detailed Status

Completed5
Terminated5
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 111 (91.7%)
Phase 21 (8.3%)

Trials by Status

active_not_recruiting18%
completed542%
recruiting18%
terminated542%

Recent Activity

2 active trials
Showing 5 of 12
recruitingphase_1

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

NCT06710223
completedphase_2

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

NCT03007732
terminatedphase_1

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

NCT05220722
terminatedphase_1

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

NCT04935229
active_not_recruitingphase_1

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

NCT05607953
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06710223Phase 1

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

Recruiting
NCT03007732Phase 2

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Completed
NCT05220722Phase 1

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Terminated
NCT04935229Phase 1

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Terminated
NCT05607953Phase 1

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Active Not Recruiting
NCT03322384Phase 1

UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

Completed
NCT02266147Phase 1

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Terminated
NCT02254772Phase 1

A Phase I/II Study of Intratumoral Injection of SD-101

Completed
NCT00823862Phase 1

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Completed
NCT00599001Phase 1

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Completed
NCT02731742Phase 1

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

Terminated
NCT01745354Phase 1

Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12